- $88.09m
- $74.94m
- $0.54m
Brief: Mainz Biomed NV - Enters Asset Purchase Agreement On April 9, 2026 For Next Gen Ip Sale - SEC Filing
Brief: Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions In Quantum And Cyber Defense Sectors
Mainz Biomed to rebrand as Quantum Cyber, shares rise
Brief: Mainz Biomed Announces U.S.$6 Million Private Placement And Strategic Update
Brief: Mainz Biomed NV - May Offer And Sell Ordinary Shares Up To $2.2 Million From Time To Time- SEC Filing
Brief: Mainz Biomed And Oncovanguard8 Enter Into Agreement To Bring Coloalert To South America
Brief: Mainz Biomed Reports Topline Results From Feasibility Study Of Biomarker Panel In Pancreatic Cancer Project
Brief: Mainz Biomed NV Files For Offering 1.5 Million Ordinary Units - SEC Filing
Brief: Mainz Biomed Initiates Feasibility Study Of Biomarker Panel In Pancreatic Cancer Project
Brief: Mainz Biomed Enters Into Technology Partnership With Edx Medical Group
Brief: Mainz Biomed NV Enrolls First Patient In Early Detect 2 Study
Brief: Mainz Biomed signs licensing deal with Liquid Biosciences
Brief: Mainz Biomed N.V. Regains Compliance With Nasdaq Capital Market Listing Requirements
Brief: Mainz Biomed Forms Agreement With Quest Diagnostics To Provide Clinical Trials Laboratory Services For Colorectal Cancer Screening Test
Brief: Mainz Biomed Announces Closing Of $8 Million Follow-On Offering
Brief: Mainz Biomed Announces Pricing Of $8.0 Million Follow-On Offering Priced At-The-Market Under Nasdaq Rules
Brief: Mainz Biomed NV Files Offering On Best Efforts Basis Up To 30.8 Million Ordinary Shares -SEC Filing
U.S. RESEARCH ROUNDUP-Abbvie, Lionsgate Studios, UnitedHealth Group
Brief: Mainz Biomed Partners With Trusted Health Advisors To Support US Go-To-Market Strategy For Next Generation Early Colorectal Cancer Diagnostic